A PHASE 1, OPEN-LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE OF AN ENCAPSULATED MICROSPHERE FORMULATION (eMS) TO THE FORMULATED CAPSULE (FC) OF CRIZOTINIB IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 24 Jan 2022
At a glance
- Drugs Crizotinib (Primary) ; Crizotinib (Primary)
- Indications Anaplastic large cell lymphoma; Bladder cancer; Cancer; Glioblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Jan 2022 Status changed from recruiting to completed.
- 10 Nov 2021 Planned End Date changed from 6 Oct 2021 to 15 Dec 2021.
- 10 Nov 2021 Planned primary completion date changed from 6 Oct 2021 to 15 Dec 2021.